Viramidine Demonstrates Better Safety Than Ribavirin in Monkeys But Not Rats

References

• Aldrich M. B., Blackburn M. R., Kellems R. E. The importance of adenosine deaminase for lymphocyte development and function. Biochem. Biophys. Res. Commun. 2000; 272: 311–315, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Apasov S. G., Blackburn M. R., Kellems R. E., Smith P. T., Sitkovsky M. VAdenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 2001; 108(1)131–141, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bloom J. C., Brand T. J. Toxic responses of the blood. Cassarett and Doull's Toxicology, The Basic Science of Poisons6th Ed., C. D. Klassen. McGraw Hill, Medical Publishing Division, New York 2001; 389–419
   Google Scholar
• Canonico P. G., Kastello M. D., Cosgriff T. M., Donovan J. C., Ross P. E., Spears C. T., Stephen E. L. Hematological and bone marrow effects of ribavirin in rhesus monkeys. Toxicol. Appl. Pharmacol. 1984; 74: 163–172, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Connor E., Morrison S., Lane J., Oleske J., Sonke R. L., Connor J. Safety and tolerance and pharmacokinetics of systemic ribavirin in children with human immunodificiency virus infections. Antimicrob. Agents Chemother. 1993; 37: 532–539, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Dean J. H., Murray M. J. Toxic responses of the immune system. Cassarett and Doull's Toxicology, The Basic Science of Poisons4th Ed., M. O. Amudur, J. Doull, C. D. Klassen. McGraw Hill, Medical Publishing Division, New York 1991; 282–333
   Google Scholar
• Di Bisceglie A. M., McHutchison J., Rice C. M. New therapeutic strategies for hepatitis C. Hepatology 2002; 35(1)224–231, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fried M. W. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36((5 Suppl 1))S237–244, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hillyard I. W. The preclinical toxicology and safety of ribavirin. RIBAVIRIN, A Broad Spectrum Antiviral Agent, R. A. Smith, W. Kirkpatrick. Academic Press, New York 1980; 59–72
   Google Scholar
• Hltgren C., Milich D. R., Weiland O., Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus‐specific immune responses. J. Gen. Virol. 1998; 79: 2381–2391, [CSA]
   PubMed Web of Science ®Google Scholar
• Lertora J. J., Rege A. B., Lacour J. T., Ferencz N., George W. J., VanDyke R. B., Agrawal K. C., Hyslop N. E. Pharmacokinetics and long‐term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Therap. 1991; 50: 442–449
   PubMed Web of Science ®Google Scholar
• Lin C. C., Yeh L. T., Vitarella D., Hong Z. Viramidine, a prodrug of ribavirin, shows better liver—targeting property and safety profiles in animals. Antivir. Chem. Chemother. 2003; 14: 145–152, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Lin C. C., Yeh L. T., Luu T., Lourenco D., Lau J. Y.N. Pharmacokinetics and metabolism of [14C] ribavirin in rats and cynomolgus monkeys. Antimicrob. Agents Chemother. 2003; 47: 1395–1398, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• NTP Report Number IMM90010. The Immunotoxicity of Ribavirin (CAS No. 36791‐04‐5) in Female C57Bl/6 Mice. National Toxicology Program (NTP), Organ System Toxicity Abstracts (Immunology Studies), August, 1989
   Google Scholar
• Page T., Conner J. D. The metabolism of ribavirin in erythrocytes and nucleated cell. Int. J. Biochem. 1990; 22: 379–383, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pol S., Nalpas B., Bourliere M., Couzigou P., Tran A., Abergel A., Zarski J. P., Berthelot P., Brechot C. Combination of ribavirin and interferon‐alfa surpasses high doses of interferon‐alfa alone in patients with genotype 1b—related chronic hepatitis C. Hepatology 2003; 31: 1338–1344, [CROSSREF]
   Google Scholar
• Tam R. C., Ramasamy K., Bard J., Pai B., Lim C., Averett D. R. The ribavirin ananlouge ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis—induced serum alanine aminotransferase levels. Antimicrob. Agents Chemother. 2000; 44(5)1276–1283, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tam R. C., Lau J. Y., Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir. Chem. Chemother. 2001; 12(5)261–272, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wu J. Z., Walker H., Lau J. Y.N., Hong Z. Activation and deactivation of a broad‐spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother. 2003; 47(1)426–431, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar